Beam Reports Positive Sickle Cell Gene Therapy Data
Beam Therapeutics says its risto-cel therapy met the primary endpoint in a pivotal Phase 1/2 trial for sickle cell disease.
Updated on Nov. 10, 2026 in Biotech
Beam Therapeutics reported positive pivotal Phase 1/2 BEACON results for risto-cel, an investigational base-edited therapy for sickle cell disease. The trial met its primary and secondary endpoints, with patients achieving at least 12 consecutive months free of severe vaso-occlusive crises.
Why it matters
Sickle cell disease is caused by a beta-globin mutation that makes red blood cells rigid and sickle-shaped, and risto-cel aims to address it by reactivating fetal hemoglobin production. Beam plans to seek regulatory approval, which would move the therapy closer to patients with the condition.
The BEACON trial enrolled 39 adults and 10 adolescents as of October 20, with 31 patients completing the required follow-up for the endpoint. Beam has not yet disclosed the proportion of patients reaching the primary efficacy endpoint or detailed safety data.
The players
Beam Therapeutics
Beam Therapeutics is a gene editing company developing base-editing therapies for serious diseases, including risto-cel for sickle cell disease.
Eli Lilly
Eli Lilly is a major pharmaceutical company that acquired gene editing firm Verve Therapeutics for up to $1.3 billion in 2025.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for reviewing and approving new therapies, including the biologics license application Beam plans to submit.
The details
Risto-cel is an ex vivo, autologous therapy in which a patient's own CD34+ hematopoietic stem cells are base-edited to inhibit the BCL11A gene, allowing fetal hemoglobin expression. In November 2024, Beam disclosed the death of a BEACON patient from respiratory failure four months after treatment, which the company deemed unrelated to risto-cel and likely linked to the busulfan-based chemotherapy regimen.
Timeline
November 2024: Beam disclosed the death of a BEACON patient from respiratory failure.
2025: Eli Lilly acquired Verve Therapeutics for up to $1.3 billion.
October 20: Cutoff date for 39 adults and 10 adolescents treated with risto-cel.
Next month: Beam will present data from an earlier cutoff at the ASH meeting in New Orleans.
Year-end 2026: Planned BLA submission to the FDA.
Big Picture
Risto-cel follows the path opened by Casgevy, the first approved CRISPR-based therapy for sickle cell disease, but uses base editing rather than DNA cutting to reactivate fetal hemoglobin. The BEACON results position Beam as a competing approach in the same therapeutic area.
If approved, risto-cel could offer a one-time treatment that aims to reduce the severe pain crises that define sickle cell disease. Patients and their families would face questions about access, cost, and eligibility once a therapy like this reaches the market.
The takeaway
Gene-editing therapies for sickle cell disease are moving from trials toward regulatory review, so patients and caregivers should watch for approval decisions and eligibility criteria. Beam's detailed data and safety disclosures will be important to evaluate the therapy's full benefit and risk.
What happens next
Beam plans to present detailed BEACON results at a medical meeting in 2027 and to submit its biologics license application to the FDA as early as year-end 2026.
Further reading
For more on the gene-editing companies behind treatments like this, see our Biotech coverage.
